Terheyden P, Kämpgen E, Rünger T M, Bröcker E B, Becker J C
Universitätshautklinik Würzburg, Gottingen.
Hautarzt. 1998 Oct;49(10):770-3. doi: 10.1007/s001050050823.
In spite of their tumor's origin in the uveal tract, many patients suffering from advanced uveal melanoma are admitted to dermatological oncology units. Most patients with metastases from uveal melanoma receive treatments that were established for stage IV cutaneous melanoma. However, both the biology as well as the metastastic behaviour of this tumor is different from cutaneous melanoma. Lymphatic metastases do not occur, and hematogeneous metastases usually occur later and predominantly involve the liver. The prognosis is very bad ranging from 2 to 5 months. We describe three patients with advanced uveal melanoma who received immunochemotherapy containing interferon-alpha 2b, interleukin-2, and fotemustine. This therapy induced a partial response of more than 49 months duration in one patient, whereas for the remaining patients the disease progression could be stabilized for eight and 16 months, respectively. This therapeutic success is reflected by a prolonged survival of 14,43+, and 59+ months.
尽管这些患者的肿瘤起源于葡萄膜，但许多患有晚期葡萄膜黑色素瘤的患者却被收治到皮肤肿瘤学科室。大多数葡萄膜黑色素瘤转移患者接受的是针对IV期皮肤黑色素瘤制定的治疗方案。然而，这种肿瘤的生物学特性以及转移行为均与皮肤黑色素瘤不同。不会发生淋巴转移，血行转移通常出现较晚，且主要累及肝脏。预后非常差，生存期为2至5个月。我们描述了三名接受包含α-2b干扰素、白细胞介素-2和福莫司汀的免疫化疗的晚期葡萄膜黑色素瘤患者。该疗法在一名患者中诱导出了持续超过49个月的部分缓解，而其余患者的疾病进展分别稳定了8个月和16个月。这种治疗成功体现在患者的生存期延长至14个月、43个月以上以及59个月以上。
